JAGUAR HEALTH, INC. Accrued Salaries, Current
JAGUAR HEALTH, INC. (JAGX) had Accrued Salaries, Current of $164.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Accrued Liabilities, Current › Employee-related Liabilities, Current
us-gaap:AccruedSalariesCurrent · last filed 2026-08-19
- 2026-06-30: Accrued Salaries, Current $164.00K.
- 2026-03-31: Accrued Salaries, Current $209.00K.
- 2025-12-31: Accrued Salaries, Current $263.00K.
- 2024-12-31: Accrued Salaries, Current $133.00K.
| Period end | Accrued Salaries, Current | Accrued Salaries, Current as first filed |
|---|---|---|
| 2026-06-30 | $164.00K 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $209.00K 10-Q · filed 2026-05-20 | |
| 2025-12-31 | $263.00K 10-Q · filed 2026-08-19 | |
| 2024-12-31 | $133.00K 10-K · filed 2026-04-07 | |
| 2023-12-31 | $208.00K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $263.00K 10-K · filed 2024-04-01 | |
| 2021-12-31 | $120.00K 10-K · filed 2023-03-24 | |
| 2020-12-31 | $43.00K 10-K · filed 2022-03-11 | |
| 2019-12-31 | $111.00K 10-K · filed 2021-03-31 | $111.09K 10-K · filed 2020-04-03 |
| 2018-12-31 | $298.96K 10-K · filed 2020-04-03 | $300.04K 10-K · filed 2019-04-10 |
| 2018-03-31 | $1.15K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $150.00 10-K · filed 2019-04-10 | |
| 2017-09-30 | $150.00 10-Q · filed 2017-11-20 | |
| 2017-06-30 | $265.00 10-Q · filed 2017-08-09 | |
| 2016-12-31 | $2.69K 10-K · filed 2018-04-09 | |
| 2016-03-31 | $19.47K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $80.69K 10-K · filed 2017-02-15 | |
| 2014-12-31 | $53.09K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |